A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

February 28, 2018

Study Completion Date

June 30, 2018

Conditions
Stage IV Melanoma
Interventions
BIOLOGICAL

A-dmDT390-bisFv(UCHT1)

anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)

BIOLOGICAL

Pembrolizumab

A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.

RADIATION

Ionizing Radiation

Electromagnetic or corpuscular radiation capable of producing ions, directly or indirectly, in its passage through matter.

Trial Locations (1)

40202

James Graham Brown Cancer Center, Louisville

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

James Graham Brown Cancer Center

OTHER

lead

Angimmune LLC

INDUSTRY

NCT02990416 - A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma | Biotech Hunter | Biotech Hunter